Proceedings · Session S-669 · filed November 20, 2026

Translational ScienceSession paper

FDA Approves Venglustat, First Oral Therapy for GD3 Neurological Symptoms

FDA approved Sanofi's venglustat on Nov. 18, 2026 as the first oral therapy for Type 3 Gaucher neurological symptoms, backed by a 43-patient head-to-head trial against enzyme replacement.

By Amara Osei4 min read715 words

Summary

  • FDA approved venglustat (Infilbray) on Nov. 18, 2026, the first treatment for neurological symptoms of Type 3 Gaucher disease in patients weighing at least 15 kg.
  • The pivotal trial enrolled 43 patients; venglustat improved a combined ataxia and cognition endpoint versus biweekly IV enzyme replacement at week 52.
  • Safety signals include serious psychiatric risks including suicidal ideation, plus animal findings on vision and fetal harm.
  • The EU approved Sanofi's VaxRabeo rabies vaccine on Nov. 19, 2026, stable up to 27 °C for 96 hours with 100% post-exposure seroconversion.
  • WHO estimates rabies causes about 59,000 deaths per year across 150 countries.
<![CDATA[What Venglustat’s Approval Means for Rare Disease Developers]]>
Figure<![CDATA[What Venglustat’s Approval Means for Rare Disease Developers]]> — AI-generated

By Amara Osei

The FDA approved venglustat (Infilbray) tablets on Nov. 18, 2026, as the first treatment for the neurological symptoms of Type 3 Gaucher disease (GD3) in adults and in pediatric patients weighing at least 15 kg. Genzyme Corporation, a Sanofi company, holds the approval, which followed Orphan Drug designation and Priority Review.

The pivotal evidence base is small: 43 patients. Regulators accepted a randomized, double-blind, multicenter study (NCT05222906) enrolling GD3 patients aged 12 and older whose systemic disease had already stabilized on enzyme replacement therapy. Participants received either oral venglustat once daily or intravenous enzyme replacement every two weeks for 52 weeks. At week 52, the venglustat arm improved on a combined measure of two neurological assessments — ataxia and cognitive function — compared with the enzyme replacement arm, which addressed only the non-neurologic manifestations of the disease. The FDA has not published effect sizes in the announcement, and the head-to-head comparator does not itself treat neurologic symptoms.

What does the drug actually do?

GD3 is a rare inherited condition in which a deficient or malfunctioning enzyme leaves the body unable to break down fatty substances called glucosphingolipids. As these accumulate in organs, tissues and the brain, patients develop worsening problems with balance, coordination, speech, memory and thinking. That central nervous system involvement separates GD3 from Type 1 Gaucher disease.

Venglustat inhibits glucosylceramide synthase, reducing the buildup throughout the body and within the brain. Acting FDA Commissioner Kyle Diamantas said: "This drug's ability to cross the blood-brain barrier means it can get to the source of the buildup driving the neurological symptoms." He added that the approval "reflects the FDA's commitment to advancing therapeutic options for patients with rare diseases."

What are the safety constraints?

The most common adverse effects were gastrointestinal symptoms and effects on mood. Serious psychiatric risks, including suicidal ideation and behavior, have been reported. Animal studies pointed to possible clouding of vision in younger patients and harm to fetal development when the drug is taken during pregnancy. Any label language on monitoring will determine how heavily these risks weigh on prescribing.

Why does the approval matter for developers?

The approval moves treatment of GD3's neurological component from a biweekly intravenous biologic to a once-daily oral solid dosage form. That shift carries different formulation, scale-up and distribution demands than infusion-based enzyme replacement products. The weight-based pediatric indication may also affect how dose strengths are developed and supplied.

The decision adds to a year of rare disease approvals reshaping development and manufacturing strategy. Expedited pathways can require scale-up and supply chain readiness to run alongside clinical development, and manufacturers serving small, geographically dispersed populations need agile, compliant production models.

Venglustat also follows September's approval of zilganersen for Alexander disease, an intrathecally delivered RNA-targeted therapy dosed quarterly. Together, the two approvals show the range of delivery strategies — from intrathecal oligonucleotides to brain-penetrant oral small molecules — that regulators now accept for neurological rare diseases.

What else did Sanofi secure this week?

Separately, Sanofi announced on Nov. 19, 2026, that the European Commission had approved VaxRabeo, a rabies vaccine using the inactivated Wistar strain, for pre-exposure and post-exposure prophylaxis in all age groups. The approval followed a positive CHMP opinion on Sept. 17, 2026.

VaxRabeo is produced using Vero cell technology and shares its viral strain with Sanofi's Verorab and Imovax Rabies vaccines. It carries a 60-month shelf life and remains stable at temperatures up to 27 °C for 96 hours before reconstitution, and its formulation is designed to minimize allergic reactions. In pre-exposure studies, two- and three-dose regimens produced protective antibody levels comparable to existing vaccines in adults and children. In post-exposure studies, 100% of participants given the vaccine intramuscularly reached protective antibody levels.

The stability profile matters most at scale. WHO estimates place rabies in 150 countries, causing roughly 59,000 deaths each year, with about 29 million people receiving post-exposure vaccination annually — a demand pool where cold-chain tolerance, not efficacy alone, decides reach.

Whether venglustat's 43-patient dataset holds up in broader real-world use, and how Sanofi prices a first-in-indication oral, will define the commercial template for the next brain-penetrant rare disease program.

via pharmtech.com (Source)

Filed under

  • venglustat
  • type-3-gaucher-disease
  • fda-approval
  • rare-disease-therapeutics
  • oral-drug-delivery
Share this article:

More from Amara Osei

Amara Osei

Show full bio

News editor covering money, funding and market shifts around research and development at Hypothesis Wire.

261 articles

References

  1. FDA Pushes Agios' Mitapivat SCD Decision to February 2027
  2. FDA Clears First Factor XIa Inhibitor, Setting Benchmark for a Crowded Class
  3. GLP-1 Trials Show 2-3 Year Biological Age Reduction, Novo Reports
  4. SNAC’s 100-to-1 Excipient Burden Frames the Oral Peptide Problem
  5. NAFDAC Listing Is Not Proof: The Case Against Animal-Only Evidence for Herbal Claims

« Previous article